FDA approves Medtronic's GEM III ICD (implantable cardioverter defibrillator):
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale Medtronic's GEM III AT implantable cardioverter defibrillator (ICD) for managing patients with ventricular tachyarrhythmia with or without atrial fibrillation. The Minneapolis, Minnesota company said the device offers a number of enhancements compared to its GEM II and Jewel AF ICDs. It includes the InCheck AT Patient Assistant, which provides: ambulatory symptom marking and heart rhythm status to the patient; an improved version of its PR Logic dual chamber detection algorithm, which increases its ability to distinguish between lethal and nonlethal arrhythmias; and increased energy output.